Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

G Coukos

Showing results (61-70 of 65) with videos related to

Pageof 7
Sort By:
You have reached the last page of results.This site can display upto 65 results.
European Journal of Cancer (Oxford, England : 1990)|February 3, 2024
Multiplexed high-throughput immune cell imaging in patients with high-risk triple negative early breast cancer: Analysis from the International Breast Cancer Study Group (IBCSG) Trial 22-00S Rusakiewicz, S Tyekucheva, S Tissot-Renaud, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|December 30, 2023
B-cell infiltration is associated with survival outcomes following programmed cell death protein 1 inhibition in head and neck squamous cell carcinomaN Gavrielatou, E Fortis, A Spathis, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|April 10, 2025
Safety of adoptive therapy with tumor-infiltrating lymphocytes and high-dose recombinant interleukin 2 in advanced cutaneous melanoma: a systematic review and meta-analysisS Martín-Lluesma, U Dafni, K Vervita, et al.
European Journal of Cancer (Oxford, England : 1990)|April 17, 2021
Late-onset and long-lasting immune-related adverse events from immune checkpoint-inhibitors: An overlooked aspect in immunotherapyE Ghisoni, A Wicky, H Bouchaab, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|April 29, 2017
A phase 2, randomized, double-blind, placebo- controlled study of chemo-immunotherapy combination using motolimod with pegylated liposomal doxorubicin in recurrent or persistent ovarian cancer: a Gynecologic Oncology Group partners studyB J Monk, M F Brady, C Aghajanian, et al.
Pageof 7

Showing results (61-70 of 65) with videos related to

Sort By:
Pageof 7
You have reached the last page of results.This site can display upto 65 results.
European Journal of Cancer (Oxford, England : 1990)|February 3, 2024
Multiplexed high-throughput immune cell imaging in patients with high-risk triple negative early breast cancer: Analysis from the International Breast Cancer Study Group (IBCSG) Trial 22-00S Rusakiewicz, S Tyekucheva, S Tissot-Renaud, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|December 30, 2023
B-cell infiltration is associated with survival outcomes following programmed cell death protein 1 inhibition in head and neck squamous cell carcinomaN Gavrielatou, E Fortis, A Spathis, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|April 10, 2025
Safety of adoptive therapy with tumor-infiltrating lymphocytes and high-dose recombinant interleukin 2 in advanced cutaneous melanoma: a systematic review and meta-analysisS Martín-Lluesma, U Dafni, K Vervita, et al.
European Journal of Cancer (Oxford, England : 1990)|April 17, 2021
Late-onset and long-lasting immune-related adverse events from immune checkpoint-inhibitors: An overlooked aspect in immunotherapyE Ghisoni, A Wicky, H Bouchaab, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|April 29, 2017
A phase 2, randomized, double-blind, placebo- controlled study of chemo-immunotherapy combination using motolimod with pegylated liposomal doxorubicin in recurrent or persistent ovarian cancer: a Gynecologic Oncology Group partners studyB J Monk, M F Brady, C Aghajanian, et al.
Pageof 7